Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Corient Private Wealth LLC Acquires 33,958 Shares of Bristol Myers ...

AI-generated analysis

📈 Corient Private Wealth LLC increased its BMY stake by 7.5%, adding 33,958 shares to a total holding of 489,348 shares valued at $26.4 million.

🏦 Institutional ownership stands at 76.41%, with new positions taken by Swiss RE Ltd., Darwin Wealth Management LLC, and Bayban in the fourth quarter.

💰 Bristol Myers Squibb announced a quarterly dividend of $0.63 per share, resulting in a 4.6% annualized dividend yield payable on August 3rd.

📊 The stock trades at $54.66 with a market cap of $111.62 billion and a P/E ratio of 15.35.

📉 Analyst consensus is 'Hold' with an average price target of $61.31, though ratings vary from 'Buy' to 'Sell' among major firms.

👔 EVP David V. Elkins sold 30,000 shares in April for approximately $1.85 million, reducing his position by 15.85%.

Bullish Signals
  • Corient Private Wealth LLC significantly increased its stake by 7.5%, signaling confidence in the company's long-term prospects.
  • Physician Wealth Advisors Inc. boosted its position by 73.5%, adding 202 shares to its holdings.
  • The company offers a substantial dividend yield of 4.6% with a payout ratio of 70.79%, providing attractive income for shareholders.
  • UBS Group and Guggenheim maintain 'Buy' ratings, indicating strong institutional support despite mixed market sentiment.
  • HSBC raised its price target from $53.00 to $60.00, suggesting potential upside from current levels.
Risk Factors
  • Wall Street Zen downgraded the stock from 'strong-buy' to 'buy', reflecting a reduction in bullish sentiment.
  • Bank of America lowered its price objective from $68.00 to $67.00, indicating a more conservative valuation outlook.
  • The stock is currently trading below its 50-day moving average of $57.25, suggesting short-term weakness or consolidation.
  • There is only one 'Sell' rating among the analysts covering the stock, highlighting some bearish perspectives.
Full Analysis
Corient Private Wealth LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 7.5% during the fourth quarter, acquiring an additional 33,958 shares to hold a total of 489,348 shares valued at $26.4 million. Several other institutional investors also adjusted their positions, including Swiss RE Ltd., Darwin Wealth Management LLC, and Physician Wealth Advisors Inc., which increased its stake by 73.5%. Collectively, institutional investors own 76.41% of the company's outstanding stock. Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Hold' and an average price target of $61.31. Major firms like UBS Group and Guggenheim maintain 'Buy' ratings, while HSBC raised its price target to $60.00. Conversely, Wall Street Zen downgraded the stock from 'strong-buy' to 'buy', and Bank of America lowered its price objective to $67.00. The company recently announced a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd. Financial metrics indicate Bristol Myers Squibb has a market capitalization of $111.62 billion and a P/E ratio of 15.35. The stock currently trades at $54.66, sitting below its 50-day moving average of $57.25 but above its 52-week low of $42.52. Key financial ratios include a current ratio of 1.42, a quick ratio of 1.28, and a debt-to-equity ratio of 2.10. EVP David V. Elkins sold 30,000 shares in April, reducing his personal holding by 15.85%.